Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 10, Number 10—October 2004
Research

Disease Susceptibility to ST11 Complex Meningococci Bearing Serogroup C or W135 Polysaccharide Capsules, North America1

Andrew J. Pollard*Comments to Author , Jan Ochnio†, Margaret Ho†, Martin Callaghan*, Mark Bigham‡, and Simon Dobson†
Author affiliations: Susceptibility to ST11 Complex Meningococci; *University of Oxford, Oxford, United Kingdom; †University of British Columbia, Vancouver, Canada; ‡Canadian Blood Services, Vancouver, Canada

Main Article

Figure 1

Incidence (cases/100,000/year) of meningococcal disease (average rates 1985–2000) in relation to serogroup C and W135 bactericidal antibody titers in British Columbia against a local ST11 outbreak isolate (AOBZ1379) and Z1582/FC978 (a Canadian clinical isolate from 2000 bearing the W135 capsule), respectively.

Figure 1. Incidence (cases/100,000/year) of meningococcal disease (average rates 1985–2000) in relation to serogroup C and W135 bactericidal antibody titers in British Columbia against a local ST11 outbreak isolate (AOBZ1379) and Z1582/FC978 (a Canadian clinical isolate from 2000 bearing the W135 capsule), respectively.

Main Article

1These data were partially presented as a poster at the International Pathogenic Neisseria Conference in Oslo, Norway, 2002.

Page created: April 11, 2011
Page updated: April 11, 2011
Page reviewed: April 11, 2011
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external